Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: geewiz who wrote (406)	11/9/1999 7:11:00 PM
From: geewiz	Read Replies (1) \| Respond to of 534

Here is a really cool chart showing market segmentation of delivery vectors! wiley.co.uk If the adenovirus vector proves successful Avigen looks to be the most likely candidate; Despite all of the apparent advantages of AAV, it has not been widely pursued due partly to its difficult manufacturing and purification process for large scale production. Production typically uses an adenovirus to initiate viral replication. The problem with this process is that using the pathogenic adenovirus can lead to contamination of AAV. Avigen, however, has developed a proprietary manufacturing process that eliminates the use of adenovirus in the manufacturing process and significantly increases yield. This may allow the company to produce AAV vectors cost effectively and in large quantities for clinical trials and commercial usage. Home page; compconsulting.com quote.yahoo.com best, art